Composition for treating intraventricular hemorrhage in preterm infants comprising mesenchymal stem cells

Patent metadata

Field	Value
Publication number	US-9539285-B2
Application number	US-201213655356-A
Country	US
Kind code	B2
Filing date	Oct 18, 2012
Priority date	Sep 7, 2012
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

Disclosed is a composition for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants comprising mensenchymal stem cells. Functioning to prevent ventricular dilatation and reduce the level of inflammatory cytokines in cerebrospinal fluid, the composition comprising mesenchymal stem cells is advantageously useful for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants. Accordingly, the composition is effectively preventive of hydrocephalus which occurs subsequent to intraventricular hemorrhage. In addition, the composition makes not only a histological and biochemical recuperation in the intraventricular hemorrhage-injured brain, but also significantly improves sensory motor functions. Mesenchymal stem cells can be used as an effective therapeutic agent because they are less prone to induce immune rejection responses and are highly likely to secrete proliferative, differentiative, and regulatory factors. Hence, mesenchymal stem cells are expected to play a critical role in the therapy of intraventricular hemorrhage in preterm infants.

First claim

What is claimed is:

1. A method of treating intraventricular hemorrhage in a preterm infant, comprising:
transplantinq allogeneic mesenchymal stem cells into a subject in need of treatment,
and
wherein the transplantation of mesenchymal stem cells is performed by intraventricular route or intravascular route.

2. The method of claim 1 , wherein the mesenchymal stem cells are selected from the group consisting of umbilical cord blood-, adipose tissue-, skin-, or bone marrow-derived mesenchymal stem cells, mesenchymal stem cells proliferated from the umbilical cord blood-, adipose tissue-, skin-, or bone marrow-derived mesenchymal stem cells by passage, and combinations thereof.

3. The method of claim 1 , wherein the transplantation of mesenchymal stem cells is by allograft.

4. The method of claim 1 , comprising further administering an auxiliary component selected from the group consisting of a culture medium, an anti-inflammatory cytokine gene, siRNA or anti-sense primer against inflammatory cytokine, an expression vector carrying the siRNA or anti-sense primer, interleukin-10, a growth factor, and a combination thereof.

5. The method of claim 1 , wherein the transplantation of mesenchymal stem cells attenuates ventriculomegaly.

6. The method of claim 1 , wherein the transplantation of mesenchymal stem cells attenuates cell death.

7. The method of claim 1 , wherein the transplantation of mesenchymal stem cells improves impaired neural myelination.

8. The method of claim 1 , wherein the transplantation of mesenchymal stem cells reduces the level of inflammatory cytokines.

Assignees

• Samsung Life Public Welfare Foundation

Inventors

• Chang Yun Sil
• Park Won Soon

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K38/2066

  IL-10 · CPC title

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title